Gattexo Logo
NPS Pharmaceuticals retained us to create a logo for their investigational compound Gattexo (teduglutide). This product is currently in Phase 3 trials and is intended to reduce dependence upon parenteral nutrition (PN) in patients with intestinal failure associated with short bowel syndrome (SBS). There are an estimated 10,000 to 15,000 SBS patients in North America who are dependent on intravenous parenteral nutrition, the cost of which can exceed $100,000 annually per patient. A vibrant bridge icon was employed to symbolize the idea of moving from an unhealthy state of life to one of hope, and the idea of nutrients being transferred to the patient.
